Department of Economics, EY Denmark, Frederiksberg, Denmark.
Middle East & Africa, Novo Nordisk Region South East Europe, Zurich, Switzerland.
Curr Med Res Opin. 2023 Aug;39(8):1055-1060. doi: 10.1080/03007995.2023.2231275. Epub 2023 Jul 10.
The glucagon-like peptide-1 agonist semaglutide and the dual glucose-dependent insulinotropic polypeptide tirzepatide have proven to significantly reduce glucose levels in people with type 2 diabetes. However, the costs needed to achieve a sustained decrease in HbA1c level and disease control with semaglutide and tirzepatide, respectively, are unclear. Therefore, this study aimed to compare the cost of treatment with semaglutide with the cost of treatment with tirzepatide for type 2 diabetes in Austria, the Netherlands, Lithuania, and the United Arab Emirates in order to determine their respective value for money.
The primary outcome of this analysis was the cost in euros needed to achieve disease control in one person with type 2 diabetes based on the composite endpoint of HbA1c <7%, ≥5% weight loss, and no hypoglycemic events. In addition, analyses regarding the cost needed to reach relevant HbA1c endpoints were performed. Clinical data were obtained from the SURPASS 2 trial, registered at clinicaltrials.gov (NCT03987919), and drug cost was based on wholesale acquisition cost or pharmacy purchase prices from public domains obtained in Q1 of 2023.
The cost needed to achieve disease control in one person with type 2 diabetes (HbA1c <7%, ≥5% weight loss, and no hypoglycemic events) was up to three times lower using semaglutide compared with all three doses of tirzepatide in most markets. In the HbA1c analyses, semaglutide was also found to be the least expensive treatment option.
Semaglutide provides better value for money than tirzepatide for HbA1c-lowering endpoints.
胰高血糖素样肽-1 激动剂司美格鲁肽和双重葡萄糖依赖性胰岛素促分泌肽替西帕肽已被证明可显著降低 2 型糖尿病患者的血糖水平。然而，尚不清楚分别使用司美格鲁肽和替西帕肽实现持续降低 HbA1c 水平和控制疾病所需的成本。因此，本研究旨在比较奥地利、荷兰、立陶宛和阿拉伯联合酋长国使用司美格鲁肽治疗的成本与使用替西帕肽治疗 2 型糖尿病的成本，以确定它们各自的性价比。
本分析的主要结局是根据 HbA1c<7%、≥5%体重减轻和无低血糖事件的复合终点，实现一名 2 型糖尿病患者疾病控制所需的欧元成本。此外，还进行了关于达到相关 HbA1c 终点所需成本的分析。临床数据来自 SURPASS 2 试验，在 clinicaltrials.gov 注册（NCT03987919），药物成本基于 2023 年第一季度从公共领域获得的批发采购成本或药店采购价格。
在大多数市场中，与替西帕肽的所有三种剂量相比，使用司美格鲁肽实现一名 2 型糖尿病患者（HbA1c<7%、≥5%体重减轻和无低血糖事件）疾病控制所需的成本最多可降低三倍。在 HbA1c 分析中，司美格鲁肽也是最具成本效益的治疗选择。
对于降低 HbA1c 的终点，司美格鲁肽比替西帕肽具有更高的性价比。
